Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440340 | 1.00 | FKBP1A (0.58) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL8223617 | 1.00 | FKBP1A (0.58) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL24358344 | 0.96 | FKBP1A (0.64) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL15893182 | 0.96 | FKBP1A (0.64) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL444202 | 0.96 | FKBP1A (0.64) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL1088066 | 0.90 | FKBP1A (0.52) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL16774272 | 0.89 | KMT2A (0.52) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL3206028 | 0.88 | HSD17B10 (0.54) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL4962228 | 0.88 | HSD17B10 (0.54) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL9933627 | 0.87 | HSD17B10 (0.53) | FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| CN-115175735-A | Antiviral compounds | 吉利德科学公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3431477-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-1276491-B9 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | UNIV PENNSYLVANIA (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1276491-B1 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | UNIV PENNSYLVANIA (US) | 2006-09-20 | — | — | EP | disclosed |
| US-7064105-B2 | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2006-06-20 | — | — | US | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | HELSINN HEALTHCARE SA (CH) | 2005-10-20 | — | — | US | disclosed |
| US-6919315-B1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-07-19 | — | — | US | disclosed |
| EP-1100824-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001726-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
| EP-0493506-A1 | CHIMERIC AMINO ACIDS AND PEPTIDES CONTAINING THESE ANALOGUES | GENENTECH, INC. (US) | 1992-07-08 | — | — | EP | disclosed |
| WO-1991004247-A1 | CHIMERIC AMINO ACIDS AND PEPTIDES CONTAINING THESE ANALOGUES | GENENTECH, INC. (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | FKBP1A 2579/4885MEN1 3636/4885KMT2A 3822/4885 |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | FKBP1A 2579/4885MEN1 3636/4885KMT2A 3822/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | FKBP1A 3305/4885MEN1 2502/4885KMT2A 3816/4885 |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | GHSR, GHRHR, MC2R | FKBP1A 956/4885MEN1 106/4885KMT2A 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.